Inhaled insulin as good as injection for children at mealtime
London:
Children with diabetes
who inhaled their mealtime doses of insulin did just as well as those who injected insulin under the skin, researchers reported at the American Diabetes Association scientific meeting in Chicago.
To regulate their blood sugar, patients with
type 1 diabetes
usually require an injection of a long-acting basal insulin once a day, plus additional injections of rapid-acting insulins at mealtimes.
MannKind's
inhaled insulin
Afrezza
is approved for use by adults but not yet for children, which prompted the study.
The 230 children with type 1 diabetes, ages 4 to 17, who participated in the trial received either Afrezza at mealtimes, or their usual mealtime injections of insulin, for 26 weeks. Everyone continued to receive their basal insulin injections.
Control of hemoglobin A1c, a marker of blood sugar control over the past several months, was comparable with the inhaled insulin and the injected insulin, the researchers found.
Inhaled insulin was also associated with less weight gain and slightly higher child and parent preference scores.
The inhaled formula did not have any adverse effects on patients' lungs, the researchers reported.
"Inhaled insulin is the fastest acting insulin available and is a valuable alternative to injected analogue insulin," study leader Dr. Michael Haller of the University of Florida said in a statement. "Afrezza should be available as an option to all children and adults with type 1 diabetes."
ONCE-WEEKLY INSULIN PROMISING FOR TYPE 2 DIABETES
Eli Lilly's experimental once-weekly insulin efsitora was comparable to daily insulins in nearly a thousand adults with type 2 diabetes in three late-stage trials, researchers reported at the ADA meeting.
The trials, which were designed to study patients at different stages of insulin use, each found efsitora to be just as effective as daily insulins for bringing HbA1c levels - a common measure of blood sugar over time - under control.
"Once-weekly efsitora may offer a significant advancement for people with type 2 diabetes who need insulin by eliminating over 300 injections per year," Lilly's senior vice president of product development, Jeff Emmick, said in a statement.
One trial, reported in The New England Journal of Medicine, involved patients with type 2 diabetes who were using insulin for the first time. A second trial in patients who had been using daily basal insulin degludec and a third trial in those who had been taking basal insulin glargine plus extra
mealtime insulin
doses were both reported in The Lancet.
Efsitora "has the potential to facilitate and simplify
insulin therapy
, reducing the hesitation often associated with starting insulin to treat type 2 diabetes," Dr. Julio Rosenstock of University of Texas Southwestern Medical Center, who led one of the studies, said in a statement.
People newly diagnosed with type 2 diabetes usually start treatment with oral medications, but roughly one-third of them will need to use insulin within 8 years of their diagnosis, according to an editorial in The Lancet.
GENETICALLY ENGINEERED SKIN GRAFTS TREAT BLISTERING DISEASE
Long-lasting wounds from a painful genetic skin disease can be healed with skin grafts genetically engineered from a patient's own cells, researchers reported in The Lancet.
In severe
dystrophic epidermolysis bullosa
, or EB, the skin is so fragile the slightest touch - even from clothing - causes blistering and wounds, eventually leading to large, open lesions that never heal.
"With our novel gene therapy technique, we successfully treated the hardest-to-heal wounds, which were usually also the most painful ones for these patients," study leader Dr. Jean Tang of Lucile Packard Children's Hospital Stanford in Palo Alto, California said in a statement.
Severe dystrophic EB is caused by a defect in the gene for collagen VII, a protein that normally holds the skin together. As a result, the layers of the skin separate in response to even slight friction.
To create the personalized skin grafts, doctors take a small biopsy sample of the patient's un-wounded skin and introduce a corrected version of the collagen VII gene to the skin cells. These cells are then grown into sheets of healthy skin.
For the late-stage study, 11 patients with recessive dystrophic EB had a total of 43 wounds treated with grafts. For each treated wound, the researchers also identified a comparable "control" wound on the same patient that was managed with traditional measures.
Six months later, 81% of treated wounds were at least half healed, compared with 16% of control wounds. Roughly two-thirds of treated wounds were at least three-quarters healed, compared with 7% of control wounds, and 16% of treated wounds had completely healed, compared with none of the control wounds.
In addition, grafted areas had less pain, itching and blistering.
The same research team had previously developed a gene therapy gel for treating smaller EB wounds.
"I hope that if these patients are diagnosed as infants and start the gene therapy gel, maybe they won't develop big wounds," Tang said. "But if the gels don't work and a wound does expand, the skin graft therapy is the right treatment. The life arc of their disease will, I hope, be modified, with less suffering."
An editorial published with the study notes that EB patients who participated in early-stage trials of the skin grafts still had decreased blistering and wounding, pain, and itch at grafted sites five years later.
In April, the U.S. Food and Drug Administration granted Abeona Therapeutics approval for the skin grafts as an EB therapy. (To receive the full newsletter in your inbox for free sign up here)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
2 days ago
- Business Standard
Stem cell breakthrough: New therapy raises hopes of curing type 1 diabetes
Living with type 1 diabetes is a constant battle where patients need to track blood sugar throughout the day and need insulin injections or pump-based therapies for life. But what if one day you could stop taking insulin for good? Today, it might sound impossible, but US-based scientists are working towards making it a reality. They have developed a new stem cell-derived treatment that has allowed the majority of patients with severe type 1 diabetes, who participated in the trial, to discontinue insulin use. The study titled Stem cell–derived, fully differentiated islets for Type 1 diabetes, published in The New England Journal of Medicine, tested an experimental treatment called zimislecel, developed by US biopharmaceutical company Vertex Pharmaceuticals. According to the research paper, it helped 83 per cent of participants achieve insulin independence and maintain stable blood sugar levels for at least one year, marking a potentially transformative step in diabetes care. What is zimislecel and what did the trial find? Researchers conducted a trial on 14 people with severe type 1 diabetes who suffered from hypoglycemic unawareness, a dangerous condition where blood sugar drops suddenly without warning signs. These patients are at risk of passing out, having seizures, or even dying from low blood sugar. According to the study, the participants received a stem cell-based infusion called zimislecel, which introduced lab-grown islet cells into their bodies. These new cells travelled to the liver and started working like natural insulin-producing cells. The findings show: 10 out of 12 surviving participants were able to completely stop using insulin within a year The remaining two patients needed significantly less insulin Patients spent over 70 per cent of their time within the healthy blood sugar range (70–180 mg/dL) Episodes of low blood sugar stopped within the first 90 days of treatment How zimislecel could change type 1 diabetes treatment According to the researchers, type 1 diabetes happens when the immune system mistakenly destroys insulin-producing islet cells in the pancreas. Without insulin, the body cannot regulate blood sugar levels, requiring lifelong insulin injections or pumps. Zimislecel changes this as it uses stem cells engineered to become islet cells, replacing what the immune system destroyed. Once inside the body, these cells settle in the liver and start regulating blood sugar like a healthy pancreas would. However, the participants in the trial also received glucocorticoid-free immunosuppressive therapy to prevent the body from attacking the newly introduced islet cells. This means that the patient might need to take immunosuppressants for life, which reduces immunity and increases the risk of infections. The study was presented at the American Diabetes Association's 85th Scientific Sessions held in Chicago from June 21–23. According to media reports, experts have cautioned that while this immunosuppression may be less risky than what's used for organ transplants, the long-term safety of zimislecel will need more years of follow-up. What's next for zimislecel and when could it be approved? Vertex Pharmaceuticals is now moving forward with phase 3 clinical trials of zimislecel. If larger studies confirm these results, the company may apply for approval from the US Food and Drug Administration (FDA) as early as next year. The cost of the treatment is still unknown, but experts agree that even the possibility of freedom from insulin is a groundbreaking leap forward. Can this stem cell therapy help with type 2 diabetes too? Zimislecel is currently being tested only in people with type 1 diabetes. Type 2 diabetes, which typically develops later in life and is related to insulin resistance rather than insulin absence, is a different disease that may not respond the same way to this therapy. However, other researchers are experimenting with procedures to cure type 2 diabetes through cell therapy. For example, scientists in China developed an artificial version of the insulin-producing cells found in the pancreas, which were then transplanted into the patient during trials that produced positive results. More research is going on in this regard to confirm the efficacy and safety of this approach before it can be widely used as a treatment. For more health updates, follow #HealthWithBS
Indian Express
3 days ago
- Indian Express
How ChatGPT and other AI tools are changing the teaching profession
For her 6th grade honors class, math teacher Ana Sepúlveda wanted to make geometry fun. She figured her students 'who live and breathe soccer' would be interested to learn how mathematical concepts apply to the sport. She asked ChatGPT for help. Within seconds, the chatbot delivered a five-page lesson plan, even offering a theme: 'Geometry is everywhere in soccer — on the field, in the ball, and even in the design of stadiums!' It explained the place of shapes and angles on a soccer field. It suggested classroom conversation starters: Why are those shapes important to the game? It proposed a project for students to design their own soccer field or stadium using rulers and protractors. 'Using AI has been a game changer for me,' said Sepúlveda, who teaches at a dual language school in Dallas and has ChatGPT translate everything into Spanish. 'It's helping me with lesson planning, communicating with parents and increasing student engagement.' Across the country, artificial intelligence tools are changing the teaching profession as educators use them to help write quizzes and worksheets, design lessons, assist with grading and reduce paperwork. By freeing up their time, many say the technology has made them better at their jobs. A poll released Wednesday by Gallup and the Walton Family Foundation found 6 in 10 U.S. teachers working in K-12 public schools used AI tools for their work over the past school year, with heavier use among high school educators and early-career teachers. It surveyed more than 2,000 teachers nationwide in April. Respondents who use AI tools weekly estimate they save them about six hours a week, suggesting the technology could help alleviate teacher burnout, said Gallup research consultant Andrea Malek Ash, who authored the report. States are issuing guidelines for using AI tools in classrooms. As schools navigate concerns over student abuse of the technology, some are also are introducing guidelines and training for educators so teachers are aware of avoiding shortcuts that shortchange students. About two dozen states have state-level AI guidance for schools, but the extent to which it is applied by schools and teachers is uneven, says Maya Israel, an associate professor of educational technology and computer science education at the University of Florida. 'We want to make sure that AI isn't replacing the judgment of a teacher,' Israel said. If teachers are using chatbots for grading they should be aware the tools are good for 'low-level' grading like multiple choice tests but less effective when nuance is required. There should be a way for students to alert teachers if the grading is too harsh or inconsistent, and the final grading decision needs to remain with the educator, she 8 in 10 teachers who use AI tools say it saves them time on work tasks like making worksheets, assessments, quizzes or on administrative work. And about 6 in 10 teachers who use AI tools said they are improving the quality of their work when it comes to modifying student materials, or giving student feedback. 'AI has transformed how I teach. It's also transformed my weekends and given me a better work-life balance,' said Mary McCarthy, a high school social studies teacher in the Houston area who has used AI tools for help with lesson plans and other said training she received from her school district on AI tools has helped her model proper use for her students. 'If I'm on the soapbox of, 'AI is bad and kids are going to get dumb,' well yeah if we don't teach them how to use the tool,' said McCarthy. 'It feels like my responsibility as the adult in the room to help them figure out how to navigate this future.'Teachers say the technology is best used sparingly Views on the role of artificial intelligence in education have shifted dramatically since ChatGPT launched in late 2022. Schools around the country initially banned it, but since then many have sought ways to incorporate it into classrooms. Concerns about student overuse and misuse are still prevalent: About half of teachers worry that student use of AI will decrease teens' ability to think critically and independently or to have persistence when problem solving, according to the study. One benefit teachers see in becoming more familiar with artificial intelligence is the ability to spot when students are overusing it. Clues that assignments are written by AI tools include an absence of grammatical errors and complex phrases in writing, said Colorado high school English teacher Darren Barkett. He said he relies on ChatGPT himself to create lesson plans and grade multiple choice tests and essays. In suburban Chicago, middle school art teacher Lindsay Johnson said she uses only AI programs vetted by her school and deemed safe to use with minors, for data privacy and other concerns. To ensure students feel confident in their skills, she said she brings the technology in only for later stages of projects. For her 8th graders' final assessment, Johnson asked them to make a portrait of an influential person in their lives. After students put final touches on their subject's face, Johnson introduced generative AI for those who wanted help designing the background. She used an AI tool within Canva, after checking with her district's IT department that the design software passed its privacy screener.'As an art teacher my goal is to let them know the different tools that are out there and to teach them how those tools work,' she said. Some students weren't interested in the help. 'Half the class said, 'I've got a vision, and am going to keep going with it.''
Time of India
3 days ago
- Time of India
Inhaled insulin as good as injection for children at mealtime
London: Children with diabetes who inhaled their mealtime doses of insulin did just as well as those who injected insulin under the skin, researchers reported at the American Diabetes Association scientific meeting in Chicago. To regulate their blood sugar, patients with type 1 diabetes usually require an injection of a long-acting basal insulin once a day, plus additional injections of rapid-acting insulins at mealtimes. MannKind's inhaled insulin Afrezza is approved for use by adults but not yet for children, which prompted the study. The 230 children with type 1 diabetes, ages 4 to 17, who participated in the trial received either Afrezza at mealtimes, or their usual mealtime injections of insulin, for 26 weeks. Everyone continued to receive their basal insulin injections. Control of hemoglobin A1c, a marker of blood sugar control over the past several months, was comparable with the inhaled insulin and the injected insulin, the researchers found. Inhaled insulin was also associated with less weight gain and slightly higher child and parent preference scores. The inhaled formula did not have any adverse effects on patients' lungs, the researchers reported. "Inhaled insulin is the fastest acting insulin available and is a valuable alternative to injected analogue insulin," study leader Dr. Michael Haller of the University of Florida said in a statement. "Afrezza should be available as an option to all children and adults with type 1 diabetes." ONCE-WEEKLY INSULIN PROMISING FOR TYPE 2 DIABETES Eli Lilly's experimental once-weekly insulin efsitora was comparable to daily insulins in nearly a thousand adults with type 2 diabetes in three late-stage trials, researchers reported at the ADA meeting. The trials, which were designed to study patients at different stages of insulin use, each found efsitora to be just as effective as daily insulins for bringing HbA1c levels - a common measure of blood sugar over time - under control. "Once-weekly efsitora may offer a significant advancement for people with type 2 diabetes who need insulin by eliminating over 300 injections per year," Lilly's senior vice president of product development, Jeff Emmick, said in a statement. One trial, reported in The New England Journal of Medicine, involved patients with type 2 diabetes who were using insulin for the first time. A second trial in patients who had been using daily basal insulin degludec and a third trial in those who had been taking basal insulin glargine plus extra mealtime insulin doses were both reported in The Lancet. Efsitora "has the potential to facilitate and simplify insulin therapy , reducing the hesitation often associated with starting insulin to treat type 2 diabetes," Dr. Julio Rosenstock of University of Texas Southwestern Medical Center, who led one of the studies, said in a statement. People newly diagnosed with type 2 diabetes usually start treatment with oral medications, but roughly one-third of them will need to use insulin within 8 years of their diagnosis, according to an editorial in The Lancet. GENETICALLY ENGINEERED SKIN GRAFTS TREAT BLISTERING DISEASE Long-lasting wounds from a painful genetic skin disease can be healed with skin grafts genetically engineered from a patient's own cells, researchers reported in The Lancet. In severe dystrophic epidermolysis bullosa , or EB, the skin is so fragile the slightest touch - even from clothing - causes blistering and wounds, eventually leading to large, open lesions that never heal. "With our novel gene therapy technique, we successfully treated the hardest-to-heal wounds, which were usually also the most painful ones for these patients," study leader Dr. Jean Tang of Lucile Packard Children's Hospital Stanford in Palo Alto, California said in a statement. Severe dystrophic EB is caused by a defect in the gene for collagen VII, a protein that normally holds the skin together. As a result, the layers of the skin separate in response to even slight friction. To create the personalized skin grafts, doctors take a small biopsy sample of the patient's un-wounded skin and introduce a corrected version of the collagen VII gene to the skin cells. These cells are then grown into sheets of healthy skin. For the late-stage study, 11 patients with recessive dystrophic EB had a total of 43 wounds treated with grafts. For each treated wound, the researchers also identified a comparable "control" wound on the same patient that was managed with traditional measures. Six months later, 81% of treated wounds were at least half healed, compared with 16% of control wounds. Roughly two-thirds of treated wounds were at least three-quarters healed, compared with 7% of control wounds, and 16% of treated wounds had completely healed, compared with none of the control wounds. In addition, grafted areas had less pain, itching and blistering. The same research team had previously developed a gene therapy gel for treating smaller EB wounds. "I hope that if these patients are diagnosed as infants and start the gene therapy gel, maybe they won't develop big wounds," Tang said. "But if the gels don't work and a wound does expand, the skin graft therapy is the right treatment. The life arc of their disease will, I hope, be modified, with less suffering." An editorial published with the study notes that EB patients who participated in early-stage trials of the skin grafts still had decreased blistering and wounding, pain, and itch at grafted sites five years later. In April, the U.S. Food and Drug Administration granted Abeona Therapeutics approval for the skin grafts as an EB therapy. (To receive the full newsletter in your inbox for free sign up here)
